1 Antibiotic Resistance related Mortality, Length of Hospital Stay, and Disability-Adjusted Life

2 Years at select Tertiary Hospitals in Uganda: A retrospective study

- 3 Authors: Jonathan Mayito¹, Flavia Dhikusooka¹, Daniel Kibombo¹, Andrew Busuge¹, Alex Andema²,
- 4 Alfred Yayi², Stephen Obbo², Richard Walwema¹, Francis Kakooza¹
- 5 1. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala P.O. Box
- 6 22418, Uganda
- 7 2. Arua, Jinja, Mbale Regional Referral Hospitals, Ministry of Health, Kampala P.O. Box 7272,
- 8 Uganda
- 9

10 Abstract

11 Background

Antimicrobial Resistance (AMR) is a major global health threat but its burden has not been extensively
described in Uganda. We aimed to investigate the antibiotic resistance related mortality, length of
hospital stays (LOS) and Disability Adjusted Life Years (DALYs).

15 Methods

This was a retrospective study of clinical records of patients with infectious syndromes admitted at Arua, Jinja and Mbale regional referral hospitals between October 2022 and September 2023. Data was abstracted from clinical records and analyzed to derive the mortality, LOS, DALYs, and factors associated with AMR and mortality using the modified Poisson regression model.

20 **Results:**

Of the 291 participants included in the analysis, 56.6% were males, 10% were living with HIV, and their median age was 35 years (IQR: 21-56). The most common infectious syndromes were sepsis (43.6%) and diarrhea (9.6%). The prevalence of antibiotic-resistant infections (ARI) was 29.6%, while that for multi-drug resistant infections (MDRI) was 17.9%. Patients at Jinja and Mbale RRHs exhibited av2.42.7his.p29391Kippits-resistant infections (MDRI) were resistant infections and second market is an analysis and the second market is a second second

26 to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while 30.8% of the ARI related mortality was due to MDR infections. Most deaths were due to sepsis (42.3%), followed by pneumonia 27 (15.4%) and meningitis (6.2%). Participants with comorbidities had higher risk of mortality due to ARI 28 (45% vs. 31% for those without comorbidities). Among Gram-negative bacteria, Escherichia coli and 29 30 Klebsiella spp contributed most to mortality, while among Gram-positives, Staphylococcus aureus and 31 Enterobacter spp contributed equally. Patients with ARI's LOS was 1.2 times higher than that for those 32 without ARI while a longer LOS was associated with a 21% higher ARI risk but a 24% decline in risk 33 of death. ARI was associated with higher DALYs, 235.4, compared to 147.0 for non-ARI. 34 Conclusion

The study revealed a high burden of AMR in Uganda, including a high prevalence of MDR and associated mortality, particularly among patients with comorbidities. This indicates an urgent need for stewardship and infection prevention strategies to control the AMR burden.

38 Key words: Antibiotic resistance, Antimicrobial resistance, AMR related mortality, length of hospital
39 stays (LOS) and Disability Adjusted Life Years (DALYs)

40

41 Background

The Murry et al 2019 review of the global AMR burden showed a glim picture of accelerated 42 progression towards the 2015 predictions on the impact of antimicrobial resistance (AMR) on global 43 health and economic growth (1). Eight years after the prediction that AMR would kill 10 million people 44 45 annually by 2050, up to 1.27 million deaths in 2019 were attributed to AMR, surpassing the previous 46 leading infectious killers including tuberculosis, malaria and Human Immuno-deficiency Virus (HIV) (1). Over one million of these deaths occurred in the World Health Organization (WHO) African region, 47 of which majority were in Western Sub-Saharan Africa (2). Worryingly, this burden that 48 49 disproportionately fell on the Africa region, coincided with poor AMR surveillance systems in the region, where the AMR preparedness score was 53% less than the overall Sub-Saharan Africa 2018-50 51 2020 Joint External Evaluation (JEE) score, with many countries lacking National Action Plans (NAP) to address the AMR scourge (3). Antimicrobial resistance has dire consequences including the use of more expensive medicines to treat infections and increased length of hospital stay, which lead to higher healthcare costs and reduced economic productivity [9]. Moreover, resistant infections make undertaking of medical procedures like organ transplants, surgeries and chemotherapy risky (4). To reverse this AMR ascendance and its impact, interventions will need to be based on a wider evidence base of the AMR burden including the clinical outcomes, AMR related economic burden, and disability, which is scarce in the WHO Africa region (1).

Despite the growing global attention on AMR, there are substantial limitations in our understanding of the burden, its distribution and the determinants at the population level (5). Currently, majority of the available AMR data describe resistance profiles or mechanism of resistance (6). While this data is important for surveillance and design of treatment protocols, data on AMR burden including clinical outcomes like mortality, disability, length of stay, and their determinant is critical in informing planning, resource mobilization and allocation, policy formulation, and the design of targeted control strategies.

Individuals who survive AMR have increased Disability Adjusted Life Years (DALYs) including the 66 years of life lost (YLL) and year lived with disability (YLD). DALYs measure the burden of disease: 67 reduction in life expectancy and diminished quality of life due to the disease (7). Consequently, studying 68 69 the distribution of DALYs in the community helps to know which communities bear the greatest burden of the disease and to focus interventions on these areas [10]. Cassini et al found that DALYs due to 70 AMR (170 per 100 000) were similar to DALYs due to influenza, tuberculosis, and HIV combined (183 71 per 100,000) and 25% (127 of 501 DALYs per 100 000) of the burden of health-care-associated 72 73 infections (HAIs) was due to AMR (8). Up to 67.9% (115 of 170) of the total DALYs were accounted for by four antibiotic-resistant bacteria: third-generation cephalosporin-resistant Escherichia coli, 74 75 Methicillin resistant Staphylococcus aureus (MRSA), carbapenem-resistant Pseudomonas aeruginosa, 76 and third-generation cephalosporin-resistant Klebsiella pneumoniae (8). The data indicates a high 77 disease burden posed by AMR.

Determination of the AMR related mortality, length of hospital stay, DALYs and the influencing factors would complement the routine surveillance data that has been accrued during the implementation of the 2018 – 2023 NAP (9-11), and offer a comprehensive description of the AMR burden in Uganda. This study therefore provides a more comprehensive description of the Uganda AMR burden in terms of attributable mortality, DALYs and the driving factors. This information is critical in the campaign to have the Uganda government adopt AMR surveillance in its health prioritization, planning, resource mobilization and allocation.

85

86 Methodology

87 This was a retrospective study of the AMR related clinical outcomes, length of hospital stay, and 88 associated factors using clinical records of patients with infectious syndromes admitted at Arua, Jinja 89 and Mbale regional referral hospitals (RRH) between October 2022 and September 2023. The records were accessed between 4th and 23rd October 2023. The researchers had access to personal identification 90 91 information during the data collection but not afterwards. Arua RRH is located in Northwest-Nile region, about 500 km from Uganda's capital, Kampala while Jinja and Mbale RRHs are located about 92 93 100 km and 400 km respectively from Kampala in the Eastern part of Uganda. Arua, Jinja, and Mbale 94 RRHs serve catchment populations of 3.5, 4.5, and 4.6 million people respectively (12-14).

95 A data abstraction form was designed, pretested and digitalized using Kobo Toolbox, a free and open-96 source suite of tools for field data collection. Digitalization included building checks in the abstraction 97 tool to ensure quality of the data collected. A team of clinicians were recruited and trained on the 98 protocol, data abstraction tool, and data collection standard operating procedures before data collection. 99 There was a two-tier review of the data by supervisors and a data manager to ensure completeness of 100 the data collected. Abstraction targeted clinical records of patients with infectious syndromes seen at the participating hospital in the 12 months prior to the study who had culture and sensitivity testing 101 done. The study variables abstracted included referral status, prior antibiotic use, admission date, 102 admission diagnosis, sampling date, comorbidities, antimicrobial susceptibility testing (AST) results, 103

antibiotics prescribed after culture, treatment outcome, length of hospital stay, and discharge date ordate of death, among others.

106 Sample size consideration

Sample size was determined using the University of San Francisco online sample size calculator (15),
based on a pooled prevalence of MRSA of 49% and 35% among HIV infected and HIV uninfected
respectively (7) and calculated odd ratios (OD) and relative risk (RR) of 1.78 and 1.4 respectively (16).
A sample size of 388 records was sufficient to determine the study variables at 80% power and 95%
confidence interval (CI).

112 Statistical analysis

Statistical analysis was conducted in Stata 18. Continuous variables were reported as median and 113 114 interquartile range (IQR) and categorical variables as proportions in terms of frequencies and percentages. The association between having or not having an Antibiotic Resistant Infections (ARI) and 115 other categorical variables was determined using the Chi-square test of independence while for 116 continuous variables, we utilized the Two-sample Wilcoxon rank-sum (also known as the Mann-117 118 Whitney) test. The resulting p-values provided the level of statistical significance for each variable examined. A modified Poisson regression model was fitted on complete cases (N=224) to determine 119 factors associated with ARI, and Prevalence Ratios at 95% CI were obtained. Factors with p-value < 120 0.2 in the un-adjusted model were selected into the adjusted model. The DALYs were calculated as a 121 122 sum of YLL and YLD. YLL was determined as number of deaths multiplied by the standard life expectancy at age of death. Since we dealt with individual data, YLL was taken as the average standard 123 124 life expectancy at age of death. YLD was determined as the number of new cases of a disease multiplied by Disability Weight (DW) multiplied by the average time a person lives with a disease before 125 126 remission. The length of hospital stay was obtained as the difference between the date of discharge or date of death and date of admission. At all levels of comparisons, a p-value of < 0.05 was taken as 127 statistically significant. 128

130 Ethical statement

- 131 The study was approved by the Makerere University School of Biomedical Sciences Institutional
- 132 Review Boards (SBS-2023-329), which granted a waiver of consent to use the clinical records of
- patients with infectious syndromes at the participating hospitals. The study was also approved by the
- 134 Uganda National Council of Science and Technology (HS3088ES).

135 RESULTS

- 136 Data was abstracted from 392 records but 101 records for tuberculosis patients were excluded from this
- analysis because they heavily skewed the data because of the characteristic long length of stay in
- 138 hospital. In *table 1*, socio-demographic characteristics of 291 participants were examined. Among them,
- 139 52.6% were males, 10% were living with HIV, and the median age was 35 years (IQR: 21-56 years).

Table 1: Distributions of demographic characteristics and other factors by antibiotic resistant infections

	Total	Antibiotic Resistant Infection (ARI)		P-value
Chanastaristis	N(C01%)	No n(Row%)	Yes n(Row%)	
Overall	291	205(70.4%)	86 (29.6%)	
Name of Facility				
Arua Regional Referral Hospital	149(51.2)	127(85.2)	22(14.8)	
Jinja Regional Referral Hospital	60(20.6)	41(68.3)	19(31.7)	
Mbale Regional Referral Hospital	82(28.2)	37(45.1)	45(54.9)	<0.001°
Sex				0.018°
Female	138(47.4)	88(63.8)	50(36.2)	
Male	153(52.6)	117(76.5)	36(23.5)	
Age in years (Median (IQR))	35(21-56)	35(24-56)	35(20-56)	0.852 ^m
Length of Hospital stay in days (Median (IQR)) (N=230)	14(6.0-31.0)	12(6.0-25.5)	25.5(10.0-43.0)	0.001 ^m
Underlying Chronic co-morbid conditions		(0.152°
No	199(68.38)	135(67.8)	64(32.2)	
Yes	92(31.62)	70(76.1)	22(23.9)	
Patient referral				0.644°
No	246(84.5)	172(69.9)	74(30.1)	
Yes	45(15.5)	33(73.3)	12(26.7)	
Referral Category (N=44)				0.579 ^f
Lower-level public health facility	32(72.73)	23(71.88)	9(28.12)	
Private health facility	12(27.27)	9(75.00)	3(25.00)	
Died (Treatment Outcome)				0.030°
No	161(55.33)	105(65.2)	56(34.8)	
Yes	130(44.67)	100(76.9)	30(23.1)	
MDRI				<0.001°
No	239(82.1)	205(85.8)	34(14.2)	
Yes	52(17.9)	0(0.0)	52(100.0)	
Prior antibiotic use				0.244 ^f
No	4(1.37)	4(100.0)	0(0.0)	

Yes	287(98.63)	201(70.0)	86(30.0)	
HIV Status				0.501°
No	262(90.0)	183(69.9)	79(30.2)	
Yes	29(10.0)	22(75.9)	7(24.1)	
Clinical Diagnosis at Admission				0.004 ^f
Diarrhea	1(0.3)	1(100.0)	0(0.0)	
Enteric fever	2(0.7)	0(0.0)	2(100.0)	
Meningitis	8(2.8)	8(100.0)	0(0.0)	
Pneumonia	28(9.6)	26(92.9)	2(7.1)	
Sepsis	127(43.6)	84(66.1)	43(33.9)	
UTI	10(3.4)	8(80.0)	2(20.0)	
Other infections	11(39.5)	78(67.8)	37(32.2)	

Col % stands for column percentage, Row % stands for row percentages, IQR stands for inter quantile range, n 142

143 stands for absolute frequencies, m stands for Mann-Whitney U test, c stands for Pearson Chi-square, and f stands for 144 Fisher's Exact test.

- 145 Prevalence of ARI and mortality

146 The prevalence ARI was 29.6%, while that for multi-drug resistant infections (MDRI) was 17.9%. Overall, mortality due to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while 147 30.8% of the mortality due to ARI, the causative pathogens were multidrug resistant (MDR), table 2. 148 The 30-day mortality was 23% compared to 30% for length of stay longer than 30 days, table 3. 149 150 Additionally, 31.6% of participants had underlying comorbid conditions, with HIV (32%) and diabetes (29%) being the most common. Participants with comorbidities had a high mortality (45%) compared 151 to those without comorbidities (31%), table 4. Sepsis (43.6%) and diarrhea (9.6%) were the most 152 153 common infectious syndromes, table 5.

Table 2: Mortality due to Antibiotic Resistant Infection 154

Characteristic (N=86)	Frequency (Col %)
Multi-Drug Resistant Infections (MDRI)	
No	239 (82.10)
Yes	52 (17.90)
Died with ARI (n=86)	
No	56 (65.10)
Yes	30 (34.90)
Died with MDRI (n=52)	
No	36 (69.20)
Yes	16 (30.80)

155

Table 3: 30-day mortality due ARI 156

<30 day mortality	
Number of people who died due to ARI with <30 day LOS and ARI	13
Total number of people that died wit ARI	56

% Mortality	23%
>30 day mortality	
Number of people who died due to ARI with >30 day LOS and ARI	17
Total number of people that died wit ARI	56
% Mortality	30%

157

158 Table 4: Mortality among those with comorbidities.

Mortality of patients with comorbidities that also had ARI	Frequency (Col %)
Number of patients who had ARI, comorbidities and also died	10
Number of patients that had ARI and comorbidities	22
Mortality due to ARI for patients with comorbidities	45%
Mortality of patients with ARI but had no comorbidities	
Number of patients who had ARI, and died but had no comorbidities	20
Number of patients that had ARI and no comorbidities	64
Mortality due to ARI for patients with comorbidities	31%

159

160 Table 5: Clinical Syndromes contributing to death

Clinical Syndrome	Number of Deaths	Percentage
Sepsis	55	42.3
Other infections	43	33.1
Pneumonia	20	15.4
Meningitis	8	6.2
Enteric fever	2	1.5
UTI	2	1.5

161

162 *Causes of mortality*

Most deaths were due to sepsis (42.3%) followed by pneumonia (15.4%) and meningitis (6.2%). Among the Gram-negative bacteria, *Escherichia coli* (7.8%) followed by *Klebsiella* spp (5.5%) contributed most to mortality while among the Gram-positives, *Staphylococcus aureus* and *Enterobacter spp* contributed equally (2.3%) to mortality. Notably, 85.7% of the deaths were due to ESKAPE organisms (*Staphylococcus aureus, Klebsiella spp, Pseudomonas aeruginosa*, and *Enterobacter* spp), *table 6*.

168 Table 6: Organisms Contributing to Mortality

Organism isolated	Frequency	Percentage
Citrobacter spp	2	1.56
Escherichia coli	10	7.81
Enterobacter spp	3	2.34
Klebsiella spp	7	5.47

Proteus spp	1	0.78
Pseudomonas spp	1	0.78
Serratia Mascessens	1	0.78
Staphylococcus aureus	3	2.34
No significant growth	100	78.13

169

170 Factors associated with ARI

171	Patients at Jinja RRH exhibited a 2.42 times higher likelihood of ARI compared to those at Arua RRH
172	(95% CI: 1.43-4.12, p=0.001). Similarly, patients at Mbale RRH had a 2.67 times higher likelihood of
173	ARI compared to those at Arua RRH (95% CI: 1.53-4.58, $p < 0.001$). A log unit increase in length of
174	hospital stay in days was associated with 21% higher risk of ARI (95% CI: (1.15-1.95), p=0.003) while
175	mortality was 1.4 (95% CI: 1.00-1.97) times higher among the ARI but this was not statistically
176	significant, table 7. For consideration of length of stay and risk of death, ARI related death ratio was
177	0.76(95% CI: 0.69-0.85), p<0.001 for the log-transformed length of hospital stay, which indicated that
178	for every one-unit log increase in the length of hospital stay, the death rate decreased by approximately
179	24% (p<0.001, 95% CI: (0.69-0.85)) for patients, <i>table 7</i> .

Table 7: Factors associated with having an antibiotic resistant infection 180

	Un-adjusted PR (95%		Adjusted PR (95%	
Characteristic	CI)	P-Value	CI)	P-value
Name of facility				
Arua Regional Referral Hospital	Reference		Reference	
Jinja Regional Referral Hospital	2.14(1.25-3.67)	0.005	2.42(1.43-4.12)	0.001
Mbale Regional Referral Hospital	3.72(2.41-5.73)	<0.001	2.65(1.53-4.58)	< 0.001
Sex				
Female	1.54(1.07-2.21)	0.019	1.49(0.96-2.32)	0.075
Male	Reference		Reference	
Length of hospital stay (per unit log increase)	1.36(1.19-1.55)	<0.001	1.50(1.15-1.95)	0.003
Age (Years)	1.00(0.99-1.01)	0.852	N/A	N/A
Underlying chronic comorbid condition				
No	Reference		Reference	
Yes	0.74(0.49-1.12)	0.164	0.71(0.44-1.13)	0.148
Patient referral				
No	Reference		N/A	N/A
Yes	0.89(0.53-1.49)	0.651	N/A	N/A
Died (Treatment outcome)				
No	Reference		Reference	
Yes	0.66(0.45-0.97)	0.034	1.31(0.88-1.96)	0.189
HIV status				
Negative	Reference		N/A	N/A
Positive	0.80(0.41-1.57)	0.517	N/A	N/A

181

182 regression model on complete cases (N=224). Factors were selected into the adjusted model if p-value<0.2 at un-adjusted.

183 Disability adjusted life years (DALYs)

- The DALYs for participants with ARI were 235.4, higher than the DALYs for participants without ARI,
 147.0.
- 186
- 187

188 Discussion

189 We provide the first description of bacterial AMR burden including mortality and DALYs in Uganda, a low-income country. Our evaluation reveals a high mortality: 34.9% due to ARI, of which 30.8% was 190 191 due to MDRI. Moreover, this mortality occurred in presence of a high rate of comorbidities including 192 HIV (32%) and diabetes (29%) and these patients with comorbidities had a higher mortality (45%) 193 compared to those without (31%). Hospital length of stay was 1.2 times higher for patients with ARI 194 compared to those without. A unit increase in length of hospital stay was associated with a 24% 195 reduction in mortality, indicating early mortality before or shortly after AMR has been diagnosed. Most death were due to sepsis, mainly as a result of Gram-negative bacteria, Escherichia coli and Klebsiella 196 spp in particular as well as Staphylococcus aureus and Enterococcus spp among the Gram-positives, 197 with the ESKAPE group accounting for 85.7% of the deaths. All these contributed to higher YLD and 198 DALYs associated with ARI: 189 and 235.4 compared to 101.7 and 147.0 for non-ARI respectively. 199

We noted a high AMR related mortality, with a significant proportion being due to MDRI, which is 200 similar to what has been observed elsewhere. Globally, AMR is surpassing previously leading 201 202 infectious causes of death: 1.27 million deaths and 4.95 million deaths were related or associated to 203 AMR in 2019, higher than that due to malaria, tuberculosis or HIV/AIDS (1). In the same year, in the 204 WHO African region, 1.05 million deaths and 250,000 deaths were due to and attributed to AMR 205 respectively, the highest mortality rate (23.5 per 100,000) globally (2). Resistant Escherichia coli, 206 among the leading six pathogens causing mortality in the same evaluation, has been associated with an 207 absolute risk of mortality of 58 - 130 per 1000 regardless of the type of resistance (17). South Asia 208 shares with Sub-Saharan Africa the brunt of the AMR burden. Overall, case fatality among neonates

209 admitted to the Neonatal Intensive Care Unit (NICU) in Vietnam was 44.4% with a 31.8% 30-day mortality rate, a 27% increase in odds of fetal outcome and a 2.1 day increase in hospital length of stay 210 (18). A systematic review by Kassim et al reported that AMR increased the mortality due to bloodstream 211 infection by 58% and doubled the risk of ICU admissions (19). The risk of death due to AMR affects 212 213 both community acquired and hospital acquired (CAI, HAI), where the resistant infections in either type 214 have a higher risk of death (20, 21). AMR has been hitherto an unrecognized infectious cause of death 215 in Uganda. In 2019, up to 7100 deaths were due to AMR while another 30700 deaths were associated with AMR, leaving Uganda with the 165th highest age standardized AMR related mortality among 204 216 217 countries (22). Moreover, the AMR related mortality was higher than the previously leading causes of 218 death including tuberculosis, HIV/AIDS and Malaria (22). In this study, the Gram-negative bacteria 219 (Escherichia coli and Klebsiella spp) were responsible for most of the deaths while Staphylococcus 220 aureus and Enterococcus spp contributed most among the Gram-positive. These were among the six 221 leading causes of death in 2019 while others included Streptococcus pneumoniae, Acinetobacter 222 baumannii, and Pseudomonas aeruginosa (1). In the African region, Streptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus, were the four leading causes of 223 death while third-generation cephalosporin-resistant Klebsiella pneumoniae and methicillin-resistant 224 225 Staphylococcus aureus (MRSA) were the leading pathogen-drug combinations associated with mortality (2). These findings highlight an urgent need to address the AMR challenge, targeting the 226 pathogens responsible for the highest burden in Uganda and the African region at large. 227

228 Diabetes and HIV/AIDS were highly prevalent among AMR patients, and although presence of 229 comorbidities was not independently associated with AMR, it carried a heightened risk of death. 230 Hyperglycemia impairs the immunity (23), increasing the risk for infectious syndromes like skin and soft tissue infections, urinary tract infections, surgical site infection, and respiratory tract infections 231 among others (24). Relatedly, drug resistant infections are also increased, for instance multidrug-232 233 resistant Klebsiella pneumoniae and MRSA were more common in hyperglycemic patients compared to normoglycemic patients (25). There has been contrasting evidence on the risk of AMR posed by 234 diabetes: higher AMR was observed in diabetic patients with liver abscess (26) while carbapenem-235

236 resistant Klebsiella. pneumoniae was lower among diabetics compared non-diabetics (27). High resistance has been noted in common bacteria isolated from diabetic foot: Staphylococcus aureus 237 against gentamicin (57.96%), and ciprofloxacin (52.45%) and Escherichia coli and Klebsiella 238 Pneumoniae resistance against common antibiotics at more than 50% (28). Overall, AMR is likely to 239 240 have a higher impact in diabetics due to their heightened risk of infection and frequent exposure to healthcare environment (29). HIV/AIDS was also highly prevalent among patients with AMR in our 241 study. HIV/AIDS weakens the immune system, making individuals prone to infections in addition to 242 243 the frequent visits to healthcare facilities, which exposes then to infections. HIV/AIDS is associated 244 with high rates of AMR (30): a systematic review showed that people living with HIV (PLWH) were 245 twice as likely to be colonized (31) or infected with MRSA, Streptococcus pneumoniae resistant to 246 penicillin, and third-generation cephalosporins resistant Escherichia coli and Klebsiella pneumoniae 247 (32). Infection prevention measures targeting individuals and hospital or home environment (33), and 248 stewardship practices in the use of antibiotics, in addition to optimized HIV/AIDS care to ensure recovery and sustenance of a robust immune system, are critical measures to protect PLWH from AMR. 249

On the other hand, we had only few cancer patients in the study as the study was done in a general ward 250 setting. Cancer is a recognized immune suppressive condition including the immune suppressive effect 251 252 of its treatment while surgery or bone marrow related cancer treatments rely on effective infection 253 prevention or treatment (34). Fifty percent (50%) of cancer deaths are due to infections but deaths due 254 to AMR have not been well described (35). However, high rates of AMR especially in ESKAPE 255 organisms, have been reported in cancer patients: Vancomycin Resistant *Enterococcus* (VRE, 80%), fluoroquinolone resistant Escherichia coli (70%), and MRSA (50%), among others (36). Consequences 256 of AMR among cancer patients include increased persistence of bacteremia (25% vs 9.7%), metastatic 257 infection (8% vs 4%), and early case-fatality rates (23% vs 11%) among infections due to resistant 258 259 ESKAPE pathogens versus other bacteria (36). Moreover, MDR is rampant in cancer patients: 40% in 260 ICU patients including 20% Escherichia coli (94.4% ESBL), 12% Staphylococcus aureus (90.6% MRSA), 12% Enterococcus faecium (18.7% VRE), and 6% Acinetobacter baumannii (36). The high 261

burden of comorbidities and associated risk of AMR and the related adverse outcomes highlight theurgent need for strategies to curtail the threat posed by the comorbidities.

Our study's finding that patients with AMR stayed 1.2 times longer in hospital than patients without 264 265 AMR, is similar to finding by a study in Ghana, where AMR patients stayed 5 days and 8 days longer than patients with susceptible infections and non-infected patients respectively (19, 37). This is far 266 more than what was found in France, where the excess length of stay due to AMR was only 1.6 days, 267 and 2.9 days in Australia (38, 39). This highlights the difference between the first world and low 268 resource settings. In the first world appropriate diagnostics can aid in early identification of AMR and 269 270 alternative options of treatment are more available. Long stay in hospital is associated with higher consumption of hospital resources, higher expenditure for the patient, loss of economic productivity 271 and risk of mortality. For instance, in the Ghana study, AMR related costs were USD 1300 higher than 272 those due to susceptible infections, with 30% of the costs being due to loss of productivity through 273 274 presenteeism and absenteeism (37). Relatedly, the average AMR related cost was less in France (USD 1173) (38) while 40% of AMR related costs in Europe and the United States were also due to loss of 275 276 productivity (40). A systematic review by Kassim et al estimated a direct cost per AMR case of USD 12,000 in low and middle income countries (LMICs) (19). Hospital acquired infections are more 277 278 commonly MDR, posing an intense challenge to healthcare. Mauldin et al found that hospital costs and length of hospital stay due to resistant Gram-negative HAI were 29.3% and 23.8% higher than those 279 280 due to susceptible Gram-negative bacteria (41). On the contrary, however, Wonziak et al did not find 281 any significant difference in length of hospital stay between drug resistant and drug susceptible CAI in Australia (20), as did Barassa et al (42) in Spain. Suzuki et al also found negligible additional length of 282 283 stay (0.8 days) attributable to resistant *Escherichia coli* and *Klebsiella* spp compared to the prolonged length of stay already imposed by bacteremia due to the same organisms (43). In our study every unit 284 285 increase in time in hospital was associated with a 24% reduction in mortality. Much as the effect of 286 AMR on length of hospital stay has been widely studied, its effect on or relation with mortality has not 287 been fully evaluated. The finding of reduced mortality with a unit increase in length of stay may imply

early mortality due AMR before appropriate diagnosis is made or before appropriate treatment isinstituted, implying that those who survive through the early events have higher chances of survival.

290 By accounting for healthy life years lost due to premature death and years lost living with disabilities, 291 DALYs offer a better estimate of burden of disease (44). We found that the DALYs due ARI (235) were almost two times higher than those due to non-ARI (147). AMR related DALYs in our setting 292 293 were close but higher than DALYs observed in Japan (195) in 2021 (45) but two and four times higher than those in Switzerland (98) and German (57) respectively in 2023 (46), highlighting that low resource 294 295 settings bear a significantly higher AMR burden. Moreover, the magnitude of DALYs can be affected 296 by type of pathogen (Staphylococcus aureus, Acinetobacter baumannii, and Streptococcus pneumoniae are associated with higher DALYS), sex (higher in male except in women in the reproductive age 297 groups), and site of infection (blood stream infections and bone and joint infection are associated with 298 higher DALYs) while geographical and socio-demographic differences have also been noted (45, 47, 299 300 48). These differences likely result from the effect of these parameters on the components used to calculate YLL and YLD particularly number of deaths, incidence of AMR cases, and disability weights. 301 302 Availability of diagnostic tests and alternative options of treatment for AMR which affect risk of death 303 or the time one stays with the resistant infection, might also explain the difference between high versus 304 low income settings.

305 We note that the admitting hospital and length of stay in hospital were independently associated with ARI. The three admitting hospitals are located within cities, however, the communities in eastern part 306 307 of the country are more urbanized than those in the north. Bacterial activity, antibiotic resistant genes, 308 and MDR bacteria in the environment have been noted to increase with urbanization and to differ by 309 level of urbanization, with population size as a key driving factor (49). Conditions in urban centers including; poor housing, poor drainage and poor sanitation; poorly-regulated and private provision of 310 medical services including access to antimicrobials, poor waste management, and increased demand for 311 312 food-animals associated with inappropriate use of antibiotics as growth-promoters, which drive 313 emergence and transmission drug resistant infection, increase with urbanization (5). Mauldin et al also 314 showed that parameters associated with increased hospital costs and length of stay respectively

315 included pneumonia diagnosis (43.8% vs. 38.2%), ICU admission (142% vs. 106%), neutropenia (83.5% vs. 70.9%) and organ transplant (115.8% vs. 74%) while patients 12 years or more had a 26.3% 316 lower hospital cost but a 66.8% lower length of stay versus those younger (41). Among patients referred 317 for long term care in Chicago, USA, presence of a feeding tube and polymicrobial infection were 318 319 associated with ARI while urinary catheter, decubitus ulcer, prior use of antibiotics and previous admission within 30 days of current admission were not (50). On the other hand, MDR Pseudomonas 320 aeruginosa infection was independently association with sex, age, and comorbidities, and correlated 321 with ventilation history and neutropenia (51). On the other hand, cotrimoxazole, amikacin, or imipenem 322 except cefazolin; admission to ICU and prior use of acid- suppressive medication were associated with 323 324 infection with MDR organisms (52). These factors can be targeted by strategies to control AMR and 325 those to improve patient outcomes.

Our study strength lies in it being the first expanded description of AMR burden in Uganda, a resource limited setting, revealing critical data that can inform strategies to control AMR, improve clinical outcomes as well as planning and resource allocation. It was limited in geographical scope as only two regions of Uganda were represented, which may not be representative of other regions in the country. Finally, because of the retrospective design, there was missing data on some of the critical parameters that would have been of interest to evaluate.

332 Conclusion/recommendation

Uganda faces a high AMR burden characterized by a high mortality and a high rate of MDR infections, high DALYs and increased length of hospital stay, in a setting of a high rate of comorbidities including HIV and diabetes. Sepsis, majorly due to resistant Gram-negative bacteria, contributed most to the AMR burden. While these findings can shape the early targeted AMR control strategies, a larger evaluation covering all regions of the country to comprehensively describe the burden is urgently needed.

339 Author contribution

- 340 Jonathan Mayito, Conceptualization, Investigation, Methodology, Project Administration, Writing -
- 341 Original Draft Preparation
- 342 Flavia Dhikusooka, statistical analysis, Review and Editing
- 343 Daniel Kibombo, Investigation, Methodology, Writing Review & Editing
- 344 Alex Andema, Writing Review & Editing
- 345 Stephen Obbo, Writing Review & Editing
- 346 Alfred Yayi, Writing Review & Editing
- 347 Richard Walwema, Resource, Methodology, Supervision, Writing Review & Editing
- 348 Francis Kakooza, Resources, Methodology, Supervision, Writing Review & Editing

349 Conflict of interest

350 All authors report no conflict of interest

351 Financial disclosure

- 352 This work was funded by the Royal Society of Tropical Medicine and Hygiene (RSTMH) Early Career
- 353 Award in partnership with the National Institute for Health and Care Research (NIHR).

354 References

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in
 2019: a systematic analysis. Lancet. 2022 Feb;399(10325):629-55.

3572.Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the358WHO African region in 2019: a cross-country systematic analysis. Lancet. 2023 Dec;12(2):E201-E16.

359 3. Elton L, Thomason MJ, tembo J, et al. Antimicrobial resistance preparedness in sub-Saharan
 360 African countries. BMC. 2020;145(9).

- 361 4. WHO. Antimicrobial resistance. [Internet]. 2021 Nov.
- Allcock S, Young EH, Holmes M, Gurdasani D, Dougan G, Sandhu MS, et al. Antimicrobial
 resistance in human populations: challenges and opportunities. Glob Health Epidemiol Genom. 2017
 May 10:2:e4.

365 6. Kivumbi MT, Standley CJ. Efforts to Identify and Combat Antimicrobial Resistance in Uganda:
366 A Systematic Review. Trop Med Infect Dis. 2021 May;6(2):86.

367 7. Global Health CEA. The DALYs. [Internet].

Cassini A, Högberg LD, Plachouras D. Attributable deaths and disability-adjusted life-years
 caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in
 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56–66.

Nabadda S, Kakooza F, Kiggundu R, et al. Implementation of the World Health Organization
 Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study
 Using National Surveillance Data. JMIR Public Health Surveill. 2021 Oct 7(10)::e29954.

Mugerwa I, Nabadda SN, Midega J, et al. Antimicrobial Resistance Situational Analysis 20192020: Design and Performance for Human Health Surveillance in Uganda. Trop Med Infect Dis. 2021
Sep;6(4):178.

Mayito J, Kibombo D, Olaro, et al. Characterization of Antibiotic Resistance in Select Tertiary
Hospitals in Uganda: An Evaluation of 2020 to 2023 Routine Surveillance Data. Trop Med Infect Dis
2024;9(4):77.

380 12. Mbale RRH. Mbale Regional Referral Hospital. [Hospital website].

381 13. Peaditric Health Intiative. Jinja Regional Referral Hospital. [Internet].

382 14. Ministry of Health. Arua Regional Referral Hospital. [Internet].

383 15. Francisco UoCS. Sample Size Calculators for designing clinical research. [Internet].

16. Olaru I D, Acconelli E, Yeung E, et al. The association between antimicrobial resistance and HIV
 infection: a systematic review and meta-analysis. CMI. 2021 Jun;27(6):P846-53.

MacKinnon MC, Sargeant JM, Pearl DL, et al. Evaluation of the health and healthcare system
 burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and
 meta-analysis.9, 200 (2020). Antimicrob Resist Infect Control 2020;9(200).

18. Peters L, Olson L, Khu DTK, Linnros S, Le NK, Hanberger H, et al. Multiple antibiotic resistance
as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive
care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. PLoS
ONE 2019;14(5):e0215666.

39319.de Kraker MEA. Understanding the impact of antimicrobial resistance on outcomes of394bloodstream infections in low- and middle-income countries. PLoS Med. 2023;20(7):e1004262.

Wozniak TM, Dyda A, Lee X. The Increased Length of Hospital Stay and Mortality Associated
 With Community-Associated Infections in Australia. Open Forum Infect Dis. 2022 Mar;9(5):ofac133.

397 21. Neubeiser A, Bonsignore M, Tafelski CS, Alefelder C. Mortality attributable to hospital
398 acquired infections with multidrug-resistant bacteria in a large group of German hospitals. Journal of
399 Infection and Public Health. 2020 Feb;13(2):204-10.

400 22. IHME. The burden of antimicrobial resistance (AMR) in Uganda. [Internet]. 2019.

401 23. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes
402 Care. 2003;26:510–3.

403 24. Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections:
404 development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020
405 Jul;202(5):953-65.

Yi H, Huang J, Guo L, Zhang Q, Qu J, M Z. Increased Antimicrobial Resistance among Sputum
Pathogens from Patients with Hyperglycemia. Infection and drug resistance. 2020;13.

Tian LT, Yao K, Zhang XY, al. e. Liver abscesses in adult patients with and without diabetes
mellitus: an analysis of the clinical characteristics, features of the causative pathogens, outcomes and
predictors of fatality: a report based on a large population, retrospective study in China. Clin Microbiol
Infect. 2012;18(E314–30).

Tian L, Tan R, Chen Y, al e. Epidemiology of Klebsiella pneumoniae bloodstream infections in
a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob
Resist Infect Control. 2016;5:48.

415 28. Wada FW, Mekonnen MF, Sawiso ED, et al. Bacterial profile and antimicrobial resistance
416 patterns of infected diabetic foot ulcers in sub-Saharan Africa: a systematic review and meta-analysis.
417 Sci Rep. 2023;13:14655.

29. Dunachie S, Chamnan P. The double burden of diabetes and global infection in low and
middle-income countries. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2019
Feb;113(2):56–64.

30. Jemal M, Deress T, Belachew T, Adem Y. Antimicrobial Resistance Patterns of Bacterial Isolates
from Blood Culture among HIV/AIDS Patients at Felege Hiwot Referral Hospital, Northwest Ethiopia.
Int J Microbiol. 2020 Oct:8893266.

424 31. Henderson HI, Ruegsegger L, Alby K, et al. Antimicrobial-resistant Enterobacterales 425 colonization in people with HIV. JAC-Antimicrobial Resistance. 2022 Aug;4(4):dlac082.

426 32. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association
427 between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. Clin
428 Microbiol Infect. 2021 Jun;27(6):846-53.

429 33. Livesley N. PROTECTING PATIENTS WITH HIV FROM ANTIMICROBIAL RESISTANT ORGANISMS.430 AMR Control. 2016 Jul.

43134.Bratti VF, Wilson BE, Fazelzad R, et al. Scoping review protocol on the impact of antimicrobial432resistance on cancer management and outcomes. BMJ Open. 2023 Feb;13(2):e068122.

433 35. Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res. 2014;161:43-434 89.

43536.AK N, HW B, VG F, et al. Antibiotic resistance in the patient with cancer: Escalating challenges436and paths forward. CA. 2021 Dec 71(6):488-504.

437 37. Otieku E, Fenny AP, Labi A, et al. Attributable Patient Cost of Antimicrobial Resistance: A
438 Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana. PharmacoEconomics
439 Open. 2023;7:257–71.

38. Touat M, Opatowski M, Brun-Buisson C, et al. A Payer Perspective of the Hospital Inpatient
Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study. Appl
Health Econ Health Policy. 2019 Jun;17(3):381-9.

443 39. Lee XJ, Stewardson AJ, Worth LJ, Graves N, Wozniak TM. Attributable Length of Stay, Mortality
444 Risk, and Costs of Bacterial Health Care-Associated Infections in Australia: A Retrospective Case-cohort
445 Study. Clin Infect Dis. 2021 May;72(10):e506-e14.

446 40. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted 447 phenomenon. Pathogens Glob Health. 2015;109(7):309–18.

448 41. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length
449 of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative
450 bacteria. Antimicrob Agents Chemother. 2010 Jan;54(1):109-15.

42. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on Morbidity, Mortality, and
Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms. Clinical Infectious
Diseases. 2017 Aug;65(4):644–52.

43. Suzuki H, Perencevich EN, Nair R, Livorsi DJ, Goto M. Excess Length of Acute Inpatient Stay
Attributable to Acquisition of Hospital-Onset Gram-Negative Bloodstream Infection with and without
Antibiotic Resistance: A Multistate Model Analysis. Antibiotics. 2020;9(2):96.

457 44. WHO. THE GLOBAL HEALTH OBSERVATORY: Explore a world of health data. [Internet].

45. Tsuzuki S, Koizumi R, Matsunaga N, al. e. Decline in Antimicrobial Consumption and Stagnation
in Reducing Disease Burden due to Antimicrobial Resistance in Japan. Infect Dis Ther 2023;12:1823–
34.

46. Gasser M, Cassini A, Lo Fo Wong D, Gelormini M, Nahrgang SA, Zingg W, et al. Associated 462 deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in 463 Switzerland, 2010 to 2019. Euro Surveill. 2023 May;28(20):2200532.

464 47. Lewandrowski KU, da Silva RCL, Elfar JC, et al. Disability-adjusted life years from bone and joint
465 infections associated with antimicrobial resistance: an insight from the 2019 Global Burden of Disease
466 Study International Orthopaedics (SICOT). 2024.

467 48. Zhang C, Fu X, Liu Y, Zhao H, G W. Burden of infectious diseases and bacterial antimicrobial
468 resistance in China: a systematic analysis for the global burden of disease study 2019. Lancet Reg
469 Health West Pac. 2023 Nov;43:100972.

470 49. Zhu J, Li R, Yan Y, Cui L. Urbanization drives the succession of antibiotic resistome and 471 microbiome in a river watershed. Chemosphere. 2022 Aug;301:134707.

Toubes EK, Singh D, Yin R, et al. Risk Factors for Antibiotic-Resistant Infection and Treatment
Outcomes among Hospitalized Patients Transferred from Long-Term Care Facilities: Does
Antimicrobial Choice Make a Difference? Clinical Infectious Diseases. 2003 Mar;36(6):724–30.

51. Shbaita S, Abatli S, Sweileh MW, al. e. Antibiotic resistance profiles and associated factors of
Pseudomonas Infections among patients admitted to large tertiary care hospital from a developing
country. Antimicrob Resist Infect Control 2023;12:149.

478 52. Alsehemi AF, Alharbi EA, Alammash BB, et al. Assessment of risk factors associated with 479 multidrug-resistant organism infections among patients admitted in a tertiary hospital - a 480 retrospective study. Saudi Pharmaceutical Journal. 2023 Jun;31(6):1084-93.

481

482

483

484